Clinical Trials
43 trialsNCT02301117 2024-09-05
A Phase I Study of TAS-102 in Patients With Advanced Solid Tumors With Renal Impairment
Taiho Oncology, Inc.
Phase 1 Completed
NCT03814005 2024-09-05
A Study of Pevonedistat in People With Blood Cancers or Solid Tumors With Kidney or Liver Problems
Takeda
Phase 1 Completed
NCT00113113 2024-08-02
Study of Rubitecan in Cancer Patients With Renal or Hepatic Dysfunction
Astex Pharmaceuticals, Inc.
Phase 1 Completed
NCT04574050 2024-03-19
SELF-BREATHE RCT for Chronic Breathlessness
King's College Hospital NHS Trust
Phase NA Completed
NCT04594161 2024-02-28
STONE
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Phase NA Completed
NCT02571036 2023-12-13
A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies
Deciphera Pharmaceuticals, LLC
Phase 1 Completed
NCT02923947 2023-11-27
Study to Assess Osimertinib in Patients w/ Adv Solid Tumours & Normal Kidney Function or Severe Kidney Impairment
AstraZeneca
Phase 1 Completed
NCT04656795 2023-05-15
PK Study in Subjects With Renal Impairment (Severe and if Required Mild & Moderate) Compared to Subjects With Normal Renal Function
Tanabe Pharma America, Inc.
Phase 1 Completed
NCT01575925 2022-11-04
POM Renal
Celgene
Phase 1 Completed
NCT01429038 2022-06-14
Mesenchymal Stem Cells After Renal or Liver Transplantation
University of Liege
Phase 1/2 Completed
NCT00634504 2022-06-06
LVPK
BTG International Inc.
Phase 1 Completed
NCT02424851 2022-01-27
OPTIMAL
Oxford University Hospitals NHS Trust
Phase 2 Completed
NCT02045017 2021-08-27
Efficacy and Safety of Pomalidomide and Dexamethasone in RRMM Patients With Renal Insufficiency
Celgene
Phase 2 Completed
NCT02668250 2021-08-26
OPTI-AGED
Centre Hospitalier Universitaire de Saint Etienne
Phase NA Completed
NCT03172884 2021-04-28
Study of Copanlisib in Hepatic or Renal Impairment
Bayer
Phase 1 Completed
NCT01337752 2020-12-17
Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency
Novartis
Phase 2 Completed
NCT00854139 2020-03-04
Combined Bone Marrow Transplantation (BMT) and Renal Transplant for Multiple Myeloma (MM) With End Stage Renal Disease (ESRD)
Massachusetts General Hospital
Phase 1 Completed
NCT00652626 2019-11-19
RENAL
Celgene
Phase 1 Completed
NCT01447914 2019-08-28
Tivantinib in Treating Patients With Relapsed, or Relapsed and Refractory Multiple Myeloma
National Cancer Institute (NCI)
Phase 2 Completed
NCT03097016 2018-04-26
A Study to Assess the Pharmacokinetics of CC-122 in Subjects With Mild, Moderate, and Severe Renal Impairment
Celgene
Phase 1 Completed
NCT01832922 2018-03-30
BR in Patients With CLL With Comorbidities and/or Renal Dysfunction
Dartmouth-Hitchcock Medical Center
Phase 1 Completed
NCT01270932 2017-12-29
Lenalidomide & High Dose Dexamethasone for Untreated Multiple Myeloma Renal Failure Patients
University Health Network, Toronto
Phase 2 Completed
NCT00483860 2017-11-13
A Phase I Topotecan Study in Subjects With Cancer and Impaired Renal Function
GlaxoSmithKline
Phase 1 Completed
NCT01331941 2017-11-06
A Pharmacokinetic Study of AMG 386 in Cancer Subjects With Normal and Impaired Renal Function
Amgen
Phase 1 Completed
NCT00721734 2017-05-02
Study of the Safety and Pharmacokinetics of Carfilzomib in Patients With Relapsed and Refractory Multiple Myeloma and Varying Degrees of Renal Function
Amgen
Phase 2 Completed
NCT00434447 2017-02-27
Long Term Efficacy and Safety of Zoledronic Acid Treatment in Patients With Bone Metastases
Novartis
Phase 4 Completed
NCT01853046 2017-02-20
Pharmacokinetics and Safety of Regorafenib (BAY73-4506) in Cancer Subjects With Severe Renal Impairment
Bayer
Phase 1 Completed
NCT00779922 2016-10-11
Pharmacokinetics of Lenalidomide (Revlimid®) in Patients With Multiple Myeloma and Impaired Renal Function
Poitiers University Hospital
Phase 2 Completed
NCT00700531 2016-10-05
EuLITE
University Hospital Birmingham
Phase NA Completed
NCT01599013 2015-12-08
JASINT1
Pierre Fabre Medicament
Phase 2 Completed
NCT01569815 2015-10-19
Pharmacokinetics of LCZ696 in Subjects With Mild and Moderate Renal Impairment Compared to Healthy Subjects With Normal Renal Function
Novartis
Phase 1 Completed
NCT01084837 2015-09-17
RENVEL
PETHEMA Foundation
Phase 2 Completed
NCT00418366 2015-08-19
A Study on the Effect of Kidney Disease on a Diabetes Medication (0431-008)
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT02063204 2015-06-30
To Assess the Pharmacokinetics, Safety and Tolerability of Selumetinib in Renal Impaired Subjects and Healthy Subjects
AstraZeneca
Phase 1 Completed
NCT00219791 2014-09-11
Study of Glucarpidase (CPG2) for the Management of Patients With Delayed Methotrexate Clearance
BTG International Inc.
Phase 2 Completed
NCT01504165 2014-02-04
Pharmacokinetics in Subjects With Renal Impairment
Merck KGaA, Darmstadt, Germany
Phase 1 Completed
NCT00750620 2013-09-05
A Pharmacokinetic Study of YM178 in Normal Subjects and Those With Mild, Moderate, and Severe Renal Impairment
Astellas Pharma Inc
Phase 1 Completed
NCT00416897 2013-08-26
Dexamethasone and Chemotherapy With or Without Plasma Exchange in Patients With Newly Diagnosed Multiple Myeloma and Acute Kidney Failure
National Cancer Institute (NCI)
Phase 3 Completed
NCT01374113 2013-03-29
Safinamide Renal Impairment Trial
Newron Pharmaceuticals SPA
Phase 1 Completed
NCT00062621 2013-02-05
Combined Bone Marrow and Kidney Transplant for Multiple Myeloma With Kidney Failure
National Institute of Allergy and Infectious Diseases (NIAID)
Phase 1 Completed
NCT00401804 2013-01-24
Bortezomib-Dexamethasone-Doxorubicin-Study
Austrian Forum Against Cancer
Phase 2 Completed
NCT00001835 2008-03-04
Oxaliplatin in Cancer Patients With Impaired Kidney Function
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT00325611 2006-05-15
Multidisciplinary Inpatient Palliative Care Intervention
Kaiser Permanente
Phase NA Completed